Ginkgo Bioworks (DNA) vs MeiraGTx (MGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MeiraGTx (MGTX) has outperformed Ginkgo Bioworks (DNA) over the past year, gaining 27.1% versus a loss of 29.5%. Over five years, MGTX leads with a -26.5% price change compared with -97.6% for DNA. MeiraGTx is the larger company by market cap ($1.03 billion vs $881.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNA | MGTX |
|---|---|---|
| Share price | $13.09 | $10.73 |
| Market cap | $881.15M | $1.03B |
| 1-day change | +15.39% | +2.19% |
| YTD return | +36.46% | +32.08% |
| 1-year return | -29.52% | +27.12% |
| 5-year return | -97.62% | -26.47% |
| P/E ratio (TTM) | — | 12.33 |
| EPS (TTM) | $-5.06 | $0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.22 | $15.35 |
| 52-week low | $5.37 | $6.62 |
| Distance from 52-week high | -28.18% | -30.10% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -46.50% | +158.62% |
| Average volume | 1.80M | 792.38K |
| Shares outstanding | 55.38M | 96.04M |
| Employees | 485 | 393 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGTX has outperformed DNA by 56.6 percentage points over the past year.
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 393 employees
DNA vs MGTX FAQ
Which is bigger, Ginkgo Bioworks or MeiraGTx?
MeiraGTx (MGTX) is larger, with a market capitalization of $1.03B compared with $881.15M for Ginkgo Bioworks (DNA).
Which stock has performed better over the past year, DNA or MGTX?
MGTX returned +27.12% over the past 12 months, compared with -29.52% for DNA (price return, excluding dividends). Past performance does not predict future results.
Are Ginkgo Bioworks and MeiraGTx in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.